Combination therapy for advanced stomach cancer before possible surgery
Part of Cancer, Digestive system clinical trials.
This clinical trial is testing a combination of three drugs—sintilimab, fruquintinib, and standard chemotherapy—as a first treatment for advanced stomach cancer that cannot be surgically removed. The goal is to see if this combination can shrink the cancer enough to allow surgery, potentially improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be confirmed as adenocarcinoma of the stomach or gastroesophageal junction by a biopsy.
- You must be between 18 and 70 years old and have not received any prior cancer treatment, including chemotherapy, radiation, or immunotherapy.
- Your cancer must be Stage IV and cannot be surgically removed, but it must involve only specific types of spread, such as certain lymph nodes, a limited number of liver spots, or cancer in the abdominal lining or ovaries.
- You must be healthy enough to undergo major abdominal surgery, and your blood tests must show adequate bone marrow, liver, and kidney function.
- You cannot have other serious uncontrolled medical conditions, active infections, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a combination of experimental drugs (IBI343, Sintilimab, and chemotherapy) before and after surgery for a specific type of stomach cancer that is CLDN18.2 positive. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
This trial tests a combination of two drugs (fruquintinib and albumin-paclitaxel) with or without an immunotherapy drug (PD-1 antibody) as a second-line treatment for advanced stomach cancer. It aims to see if adding immunotherapy improves outcomes for people who have already received immunotherapy before.
This trial tests a combination of two targeted drugs (fruquintinib and sintilimab) plus standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of three treatments (fruquintinib, sintilimab, and SOX chemotherapy) given before and after surgery for stomach cancer. The goal is to see if this approach helps shrink the tumor and improves outcomes.
This trial tests a combination of three drugs—sintilimab (an immunotherapy), nab-paclitaxel, and tegafur/gimeracil/oteracil—as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and control the disease.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.